子类别 報告 [0/1] 專利 [0/11] 期刊論文 [193/194] 會議論文/會議摘要 [41/48] 邻近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳立宗 [443/510] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群统计 近3年内发表的文件:0(0.00%) 含全文笔数:234(92.13%) 文件下载次数统计 下载大于0次:234(100.00%) 下载大于100次:234(100.00%) 全文下载总次数:146989(2.74%) 最后更新时间: 2024-12-01 08:32 上传排行 数据加载中..... 下载排行 数据加载中..... 最近上传 Identification of prognostic biomar... A novel NRF2/ARE inhibitor gossypol... Targeting lysosomal cysteine protea... c-MYC-directed NRF2 drives malignan... Ephrin A4-ephrin receptor A10 signa... Phase I dose-escalation study of SC... Germline susceptibility variants im... Index of cancer-associated fibrobla... The SMAC mimetic LCL161 is a direct... The tumor suppressor TGFBR3 blocks ...

跳至: (选择年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (选择月份) January February March April May June July August September October November December 或输入年份:

由新到旧排序 由最旧的开始

显示项目176-200 / 254. (共11页) << < 2 3 4 5 6 7 8 9 10 11 > >> 每页显示[10|25|50]项目

日期	题名	關聯
2009-12-01	芳香羰吲哚化合物	I317634/2009-12-01
2009-12	Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent	Journal of Clinical Oncology. 2009 Dec;27(36):e271.
2009-09	Synergistic augmentation of arsenic trioxide-induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors	EJC Supplements. 2009 Sep;7(3):16.
2009-08-13	Synthesis and evaluation of 3-aroylindoles as anticancer agents: Metabolite approach	Journal of Medicinal Chemistry. 2009 Aug 13;52(15):4941-4945.
2009-07-23	Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity	Journal of Medicinal Chemistry. 2009 Jul 23;52(14):4221-4233.
2009-07-03	Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers	Molecular Cancer. 2009 Jul 3;8:Article number 43.
2009-05-20	Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2009 May 20;27(15s):Abstract number 4587.
2009-05-05	Indole compounds	US7528165B2/2009-05-05
2009-05	Down-regulation of survivin enhances sensitivity to BPROL075 in human cancer cells via caspase-independent mechanisms	Cancer Research. 2009 May;69:Abstract number 5542.
2009-04-17	Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents	ChemMedChem. 2009 Apr 17;4(4):588-593.
2009-04	Aurora kinase inhibitors in preclinical and clinical testing	Expert Opinion on Investigational Drugs. 2009 Apr;18(4):379-398.
2009-04	Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis	Journal of the National Comprehensive Cancer Network. 2009 Apr;7(4):423-427.
2009-03	Advances in Aurora kinase inhibitor patents	Expert Opinion on Therapeutic Patents. 2009 Mar;19(3):321-356.
2008-12-25	Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents	Journal of Medicinal Chemistry. 2008 Dec 25;51(24):8163-8167.
2008-11-25	Anti-tumor compounds	US7456289B2/2008-11-25
2008-10-28	Human DNA polymerase eta activity and translocation is regulated by phosphorylation	Proceedings of the National Academy of Sciences of the United States of America. 2008 Oct 28;105(43):16578-16583.
2008-10	Modern staging and utility of PET imaging in esophageal cancer management	Journal of the National Comprehensive Cancer Network. 2008 Oct;6(9):862-869.
2008-08	Transcriptional repression of O-6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N '-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells	Molecular Pharmacology. 2008 Aug;74(2):517-526.
2008-07-24	Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors	Journal of Medicinal Chemistry. 2008 Jul;51(14):4351-4355.
2008-05-01	抗腫瘤化合物	I296195/2008-05-01
2008-02	A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells	Anti-Cancer Drugs. 2008 Feb;19(2):151-158.
2007-11-15	Tamoxifen accelerates proteasomal degradation of O-6-methylguanine DNA methyltransferase in human cancer cells	International Journal of Cancer. 2007 Nov;121(10):2293-2300.
2007-10	A novel oral indoline-sulfonamide agent, N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule	Journal of Pharmacology and Experimental Therapeutics. 2007 Oct;323(1):398-405.
2007-10	Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy	Expert Opinion on Therapeutic Patents. 2007 Oct;17(10):1227-1240.
2007-09-06	4-and 5-aroylindoles as novel classes of potent antitubulin agents	Journal of Medicinal Chemistry. 2007 Sep;50(18):4548-4552.

显示项目176-200 / 254. (共11页) << < 2 3 4 5 6 7 8 9 10 11 > >> 每页显示[10|25|50]项目